Drug Profile


Alternative Names: APG-101; Apocept; Asinercept; CAN-008

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apogenix
  • Developer Apogenix; CANbridge Life Sciences
  • Class Antineoplastics; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Apoptosis inhibitors; Fas ligand protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Glioblastoma; Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes - Glioblastoma; Myelodysplastic syndromes

Highest Development Phases

  • Phase II Glioblastoma
  • Preclinical Solid tumours
  • No development reported Graft-versus-host disease; Myelodysplastic syndromes; Myocardial infarction; Stroke

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes in Germany (IV)
  • 05 Oct 2017 Asunercept receives Orphan Drug status for Myelodysplastic syndromes in European Union
  • 29 May 2017 Asunercept receives Priority Medicine (PRIME) status for Glioblastoma in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top